| Literature DB >> 29708525 |
Alessandro De Vita1, Laura Mercatali2, Giacomo Miserocchi2, Chiara Liverani2, Chiara Spadazzi2, Federica Recine2, Alberto Bongiovanni2, Federica Pieri3, Davide Cavaliere4, Valentina Fausti2, Dino Amadori2, Toni Ibrahim2.
Abstract
Soft tissue sarcomas (STS) represent a spectrum of heterogeneous malignancies with a difficult diagnosis, classification, and management. To date, more than 50 histological subtypes of these rare solid tumors have been identified. Thus, due to their extraordinary diversity and low incidence, our understanding of the biology of these tumors is still limited. Patient-derived cultures represent the ideal platform to study STS pathophysiology and pharmacology. We thus developed a human preclinical model of STS starting from tumor specimens harvested from patients undergoing surgical resection. Patient-derived STS cell cultures were obtained from the surgical specimens by collagenase digestion and isolated by filtration. Cells were counted, seeded, and left for 14 days in standard monolayer cultures and then processed by downstream analysis. Before performing molecular or pharmaceutical analyses, the establishment of STS primary cultures was confirmed through the evaluation of cytomorphologic features and, when available, immunohistochemical markers. This method represents a useful tool 1) to study the natural history of these poorly explored malignancies and 2) to test the effects of different drugs in an effort to learn more about their mechanisms of action.Entities:
Mesh:
Year: 2018 PMID: 29708525 PMCID: PMC5933451 DOI: 10.3791/56767
Source DB: PubMed Journal: J Vis Exp ISSN: 1940-087X Impact factor: 1.355